Phase II Study Explores Daratumumab for High-Risk MGUS and Low-Risk SMM to Slow Multiple Myeloma Progression

Researchers have reported promising findings from the Phase II D-PRISM study, which examined the use of daratumumab in patients with high-risk monoclonal gammopathy of undetermined significance (MGUS) and low-risk smoldering multiple myeloma (SMM). These conditions are considered precursor stages to multiple myeloma, a type of blood cancer. The study focused on evaluating the efficacy and safety of daratumumab, an antibody-based therapy, in slowing disease progression in these early stages.

The investigation targeted patients with MGUS and SMM who are at elevated risk for developing full-blown multiple myeloma. Traditionally, these conditions have been managed through observation without active treatment until symptoms or progression occur. The D-PRISM study explored whether early intervention with daratumumab could alter the course of these precursor diseases. Researchers assessed clinical outcomes such as response rates, disease stabilization, and adverse effects associated with the therapy. Further details regarding specific results were not disclosed in this report but indicate potential advancements in managing early-stage hematological disorders.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 8, 2026

Author

GOAI